Mice express full-length protein ZBP1-L as well as an alternatively-spliced shorter isoform (ZBP1-S) containing only its two ...

CRISPR Therapeutics' first therapy is called Casgevy. It treats sickle cell disease (SCD) and beta thalassemia, both rare inherited illnesses that affect the function of a person's red blood cells. It ...

These cells deploy complex cytoskeletal rearrangements to recognize and eliminate potential threats 3. Even in the steady state, myeloid cells constantly survey their surroundings for potential ...

NSD-2 is crucial for AR activity in prostate cancer, promoting tumor growth and offering a potential therapeutic target for advanced prostate cancer treatment.

VRTX is a good stock to have in one's portfolio based on its strong overall financial performance and robust pipeline ...

No patients have received Casgevy, CRISPR Therapeutics and Vertex Pharmeceuticals’ recently approved sickle cell gene therapy ...

In the assessment of 12-month price targets, analysts unveil insights for Intellia Therapeutics, presenting an average target ...

The researchers first compared 4 gene-editing platforms to establish SF3B1 mutant cell lines: CRISPR-Cas9 editing, AAV HDR editing, base editing and prime editing. Prime editing was shown to be more ...

PRMT5-targeting drugs, currently tested in clinical trials for other malignancies, were assessed in human CCA cell lines and organoids, as well as in two immunocompetent CCA mouse models.

In a new study published in the Journal of Cell Science, Associate Professor at the Department of Biochemistry, Sandeep ...

During protein synthesis, or translation, genetic information transcribed in the cell's mRNA directs the stringing together ...